Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 1847-1854

  Solomkin, Joseph S ^a   Ramesh, Mayakonda Krishnamurthy ^b   Cesnauskas, Gintaras ^c   Novikovs, Nikolajs ^d   Stefanova, Penka ^e   Sutcliffe, Joyce A ^f   Walpole, Susannah M ^f   Horn, Patrick T ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Victoria Hospital   (India)

^c Department of Endoscopy   (Lithuania)

^d Daugavpils Regional Hospital   (Latvia)

^e Clinic of General Surgery Second Surgery Clinic UMHAT Sveti Georgi EAD Plovdiv   (Bulgaria)

^f Tetraphase Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERAVACYCLINE; ERTAPENEM; PLACEBO;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADULT DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; CHOLECYSTITIS; COMMUNICABLE DISEASE; CONTROLLED STUDY; DIVERTICULITIS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; ECG ABNORMALITY; FEMALE; FOLLOW UP; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEART ATRIUM FIBRILLATION; HOSPITAL PATIENT; HUMAN; ILEUS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROBIAL SENSITIVITY TEST; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NONHUMAN; PERITONITIS; PHASE 2 CLINICAL TRIAL; PHYSICAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOPHLEBITIS;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84896926830     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01614-13     Document Type: Article

References (23)

1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin. Infect. Dis. 50:133-164. http://dx.doi.org/10.1086/649554.
2. Boucher HW, Talbot GH, Bradley JE, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellbery B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12. http://dx.doi.org/10.1086/595011.
3. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of carbapenemases. Front. Microbiol. 4:48. http://dx.doi.org/10.3389/ fmicb.2013.00048.
4. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb. Mortal. Wkly. Rep. 62:165-170. http://www.cdc.gov/mmwr/pdf/wk/mm6209.pdf.
5. Kanj SS, Kanafani ZA. 2011. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin. Proc. 86:250-259. http://dx.doi.org/10.4065/mcp.2010.0674.
6. Gupta N, Limbago BM, Patel JB, Kallen AJ. 2011. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin. Infect. Dis. 53: 60-67. http://dx.doi.org/10.1093/cid/cir202.
7. Nordmann P, Cuzon G, Naas T. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236. http://dx.doi.org/10.1016/S1473-3099(09)70054-4.
8. Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA. 2012. Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6- deoxytetracycline: a potent, broad spectrum antibacterial agent. J. Med. Chem. 55:597-605. http://dx.doi.org/10.1021/jm201465w.
9. Chopra I. 2001. Glycylcyclines: third-generation tetracycline antibiotics. Curr. Opin. Pharmacol. 1:464-469. http://dx.doi.org/10.1016/S1471- 4892(01)00081-9. (Pubitemid 33593834)
10. Roberts MC. 2005. Update on acquired tetracycline resistance genes. FEMS Microbiol. Lett. 245:195-203. http://dx.doi.org/10.1016/j.femsle.2005.02.034. (Pubitemid 40523635)
11. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel florocycline, against hospital and community pathogens. Antimicrob. Agents Chemother. 57:5548-5558. http://dx.doi.org/10.1128/AAC.01288-13.
12. Clopper CJ, Pearson ES. 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413. http://dx.doi.org/10.1093/biomet/26.4.404.
13. Chan IS, Zhang Z. 1999. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 55:1202-1209. http://dx.doi.org/10.1111/j.0006-341X.1999.01202.x.
14. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457-481. http://dx.doi.org/10.1080/ 01621459.1958.10501452.
15. Wilcoxon F. 1945. Individual comparisons by ranking methods. Biom. Bull. 1:80-83. http://dx.doi.org/10.2307/3001968.
16. International Federation of Pharmaceutical Manufacturers and Associations. 2011. Medical dictionary for regulatory activities, version 14.0. International Federation of Pharmaceutical Manufacturers and Associations, Geneva, Switzerland.
17. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides ASatishchandran V, Teppler H. 2003. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a doubleblind, randomized comparative phase III trial. Ann. Surg. 237:235-245. http://dx.doi.org/10.1097/01.SLA. 0000048551.32606.73, http://dx.doi.org/10.1097/00000658-200302000-00013.
18. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. 2007. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg. Infect. (Larchmt.) 8:15-28. http://dx.doi.org/10.1089/sur.2006.030. (Pubitemid 46598292)
19. Zhanel GG, Johanson C, Embil JM, Noreddin A, Gin A, Vercaigne L, Hoban DJ. 2005. Ertapenem: review of a new carbapenem. Expert Rev. Anti Infect. Ther. 3:23-39. http://dx.doi.org/10.1586/14787210.3.1.23. (Pubitemid 40277836)
20. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, DiPersio J. 2010. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob. Agents Chemother. 54:3031-3034. http://dx.doi.org/10.1128/AAC.01808-09.
21. Sartelli M, Catena F, Ansaloni L, Leppaniemi A, Taviloglu K, van Goor H, Viale P, Lazzareschi DV, Coccolini F, Corbella D, de Werra C, Marrelli D, Colizza S, Scibè R, Alis H, Torer N, Navarro S, Sakakushev B, Massalou D, Augustin G, Catani M, Kauhanen S, Pletinckx P, Kenig J, Di Saverio S, Jovine E, Guercioni G, Skrovina M, Diaz-Nieto R, Ferrero A, Rausei S, Laine S, Major P, Angst E, Pittet O, Herych I, Agresta F, Vettoretto N, Poiasina E, Tepp J, Weiss G, Vasquez G, Vladov N, Tranà C, Delibegovic S, Dziki A, Giraudo G, Pereira J, Tzerbinis H, van Dellen D, Hutan M, Vereczkei A, Krasniqi A, Seretis C, Mesina C, Rems M, Campanile FC, Coletta P, Uotila-Nieminen M, Dente M, Bouliaris K, Lasithiotakis K, Khokha V, Zivanovic D, Smirnov D, Marinis A, Negoi I, Ney L, Bini R, Leon M, Aloia S, Huchon C, Moldovanu R, de Melo RB, Giakoustidis D, Ioannidis O, Cucchi M, Pintar T, Krivokapic Z, Petrovic J. 2012. Complicated intra-abdominal infections in Europe: a comprehensive review of the CIAO study. World J. Emerg. Surg. 7:36-44. http://dx.doi.org/10.1186/1749-7922- 7-36.
22. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl 5):S354-S367. http://dx.doi.org/10.1086/431676. (Pubitemid 41170382)
23. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-522. Clinical and Laboratory Standards Institute, Wayne, PA.